Old Web
English
Sign In
Acemap
>
authorDetail
>
X Shu
X Shu
Novartis
Indacaterol
Mometasone furoate
Medicine
Asthma
Exacerbation
6
Papers
53
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Indacaterol/Glycopyrronium/Mometasone Furoate Improves Lung Function and Reduces Exacerbations Versus Long-Acting β2-Agonist/Inhaled Corticosteroid Standard-of-Care in Patients with Uncontrolled Asthma: The Phase III IRIDIUM Study
2020
Huib A. M. Kerstjens
Jorge Maspero
Kenneth R. Chapman
R van Zyl-Smit
M. Kato
Motoi Hosoe
A.-M. Tanase
Catherine Lavecchia
Abhijit Pethe
X Shu
Peter DAndrea
Show All
Source
Cite
Save
Citations (0)
Medium-Dose Indacaterol/Glycopyrronium/Mometasone Furoate Fixed-Dose Combination Improves Lung Function Compared with High-Dose Indacaterol/Mometasone Furoate and Salmeterol/Fluticasone and Reduces Exacerbation Rates Versus High-Dose Salmeterol/Fluticasone in Moderate-to-Severe Asthma: The IRIDIUM Study
2020
Alberto Papi
Marc Humbert
Konstantinos Kostikas
C. Domingo
Jorge Maspero
Motoi Hosoe
A.-M. Tanase
Abhijit Pethe
X Shu
Peter DAndrea
Show All
Source
Cite
Save
Citations (0)
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study
2020
The Lancet Respiratory Medicine
Richard N. van Zyl-Smit
Matthias Krull
Christian Gessner
Yasuhiro Gon
Oliver Noga
Alexia Richard
Amy de los Reyes
X Shu
Abhijit Pethe
A.-M. Tanase
Peter DAndrea
Show All
Source
Cite
Save
Citations (17)
1